616-06-8

Basic information

• Product Name: DL-Norleucine
• Synonyms: (+/-)-2-AMINOCAPROIC ACID;2-AMINOHEXANOIC ACID;CH3-(CH2)3-CH(NH2)-COOH;DL-NORLEUCINE;DL-ALPHA-AMINO-N-CAPROIC ACID;DL-2-AMINO-CAPROIC ACID;DL-2-AMINOHEXANOIC ACID;DL-2-AMINO-N-HEXANOIC ACID
• CAS NO: 616-06-8
• Molecular Formula: C₆H₁₃NO₂
• Molecular Weight: 131.17
• EINECS: 210-462-7
• Product Categories: Amino Acids;Unusual Amino Acids;Amino Acid Derivatives
• Mol File: 616-06-8.mol
• Article Data: 26

Chemical Properties

• Melting Point: >300 °C(lit.)
• Boiling Point: 234 °C at 760 mmHg
• Flash Point: 95.3 °C
• Appearance: white to off-white crystalline powder
• Density: 1.1720
• Refractive Index: 1.4630 (estimate)
• Storage Temp.: Store at RT.
• Solubility: 11.49 g/L (25°C)
• PKA: pK1:2.335(+1);pK2:9.834(0) (25°C)
• Water Solubility: 11.49 g/L (25 ºC)
• Merck: 14,6706
• BRN: 1721748
• CAS DataBase Reference: DL-Norleucine(CAS DataBase Reference)
• NIST Chemistry Reference: DL-Norleucine(616-06-8)
• EPA Substance Registry System: DL-Norleucine(616-06-8)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• TSCA: Yes
• Hazardous Substances Data: 616-06-8(Hazardous Substances Data)

Usage

Chemical Properties

white to off-white crystalline powder

Definition

ChEBI: An alpha-amino acid that is caproic acid substituted by an amino group at position 2.

Biochem/physiol Actions

DL-Norleucine is a nonsulfur analogue of methionine that stimulates synthesis of cephalosporin C.

Purification Methods

Crystallise norleucine from water or aqueous MeOH. [Huffman & Ingersoll JAm Chem Soc 73 3366 1951, Beilstein 4 III 1386, 4 IV 2628.]

InChI:InChI=1/C6H13NO2/c1-2-3-4-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)

Upstream product

• 616-05-7 2-bromohexanoic acid 
• 855913-27-8 2-cyano-hexanoic acid hydrazide 
• 109-65-9 1-bromo-butane 
• 69555-14-2 ethyl N-diphenylmethylene glycine 
• 84713-70-2 [(4-chloro-benzylidene)-amino]-acetic acid ethyl ester 
• 327-56-0 D-norleucine 
• 327-57-1 L-Norleucine 
• 42930-39-2 n-butylzinc chloride 
• 152071-32-4 methylene blue 
• 142-62-1 hexanoic acid 
• 1540-29-0 ethyl 2-butylacetoacetate 
• 94626-53-6 heptane-2,3-dion-3-(O-ethyl oxime ) 
• 42563-84-8 heptane-2,3-dione 3-oxime 
• 110-43-0 n-pentyl methyl ketone 

Downstream Products

• 5665-74-7 2-amino-1-hexanol 
• 15027-13-1 N-benzyloxycarbonylnorleucine 
• 7682-16-8 N-acetylnorleucine 
• 1261072-86-9 N-methoxycarbonyl-norleucine 
• 67206-26-2 2-(2-chloroacetamido)hexanoic acid 
• 108244-71-9 N-benzenesulfonyl-DL-norleucine 
• 90697-05-5 N-(3,5-Dinitrobenzoyl)-DL-n-leucine 
• 626-97-1 pentamide 
• 110-62-3 pentanal 
• 124-38-9 carbon dioxide 
• 144701-20-2 Fmoc-norleucine 
• 34337-17-2 N-(4-chlorobenzoyl)norleucine 
• 1361143-13-6 N-2-furoylnorleucine 4-tert-butylbenzyl thioester 
• 93773-63-8 WS 30581 B 

Relevant articles and documents

CuFe2O4@PDA magnetic nanomaterials with a core-shell structure: Synthesis and catalytic application in the degradation of methylene blue in water

In this paper, core-shell polydopamine (PDA)-encapsulated CuFe2O4 (CuFe2O4@PDA) magnetic nanoparticles (MNPs) were synthesized through in situ self-polymerization for the first time. The size of the core-shell product can be controlled by tuning the dopamine monomer concentration. The formation of a PDA layer effectively enhanced the catalytic performance and provided a large specific surface area which offered more active sites for the effective interaction. The as-synthesized CuFe2O4@PDA MNPs were characterized and their catalytic activity was evaluated using the degradation of methylene blue (MB) in the presence of H2O2 as a model reaction. The experimental results showed that MB could be degraded efficiently using CuFe2O4@PDA MNPs as a catalyst. Under the optimized conditions, the degradation efficiency of MB was above 97%. Furthermore, a possible reaction mechanism was discussed. Finally, the catalyst was used for effective degradation of MB in a Yellow River water sample, which indicates its potential for practical applications in water pollutant removal and environmental remediation.

Biocatalytic asymmetric synthesis of unnatural amino acids through the cascade transfer of amino groups from primary amines onto keto acids

Flee to the hills: An unfavorable equilibrium in the amino group transfer between amino acids and keto acids catalyzed by α-transaminases was successfully overcome by coupling with a ω-transaminase reaction as an equilibrium shifter, leading to efficient asymmetric synthesis of diverse unnatural amino acids, including L-tert-leucine and D-phenylglycine. Copyright

Growth Hormone Secretagogue Receptor 1A Ligands

The present invention relates to new growth hormone secretagogue receptor 1A (GHS-R 1A) ligands, and pharmaceutical compositions comprising any of the new GHS-R1 A ligands. The ligands are suitable for a wide range of applications, and thus the present invention also relates to use of the GHS-R1 A ligands according to the present invention in the manufacture of a medicament for the treatment of an individual in need thereof. In another aspect, the present invention relates to a method of treatment of an individual in need thereof, comprising administering to said individual one or more of the GHS-R1A ligands disclosed herein, such as e.g. for treatment of cancer cachexia.